Stock DVLA PT DARYA-VARIA LABORATORIA TBK
Add to a list
To use this feature you must be a member
Log inSign up

Financials PT Darya-Varia Laboratoria Tbk

Equities

DVLA

ID1000117203

Pharmaceuticals

End-of-day quote INDONESIA S.E.
Other stock markets
 03:30:00 28/06/2024 am IST 		5-day change 1st Jan Change
1,520 IDR +1.00% Intraday chart for PT Darya-Varia Laboratoria Tbk -6.17% -8.71%
29/04 PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
22/03 PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 21,64,935 25,15,665 27,10,400 30,80,000 26,54,400 18,64,800
Enterprise Value (EV) 1 18,58,819 21,76,617 24,46,076 25,19,685 22,99,267 16,26,231
P/E ratio 10.8 x 11.3 x 16.7 x 21 x 17.8 x 12.7 x
Yield 5.52% 4.76% 4.55% 4.15% 5.02% 6.49%
Capitalization / Revenue 1.27 x 1.39 x 1.48 x 1.62 x 1.38 x 0.99 x
EV / Revenue 1.09 x 1.2 x 1.34 x 1.33 x 1.2 x 0.86 x
EV / EBITDA 6.03 x 6.08 x 9.24 x 10 x 9.25 x 6.57 x
EV / FCF -58.7 x 13.3 x 50.3 x 8.26 x -19.1 x -203 x
FCF Yield -1.7% 7.54% 1.99% 12.1% -5.23% -0.49%
Price to Book 1.8 x 1.93 x 2.04 x 2.23 x 1.89 x 1.33 x
Nbr of stocks (in thousands) 11,15,946 11,18,073 11,20,000 11,20,000 11,20,000 11,20,000
Reference price 2 1,940 2,250 2,420 2,750 2,370 1,665
Announcement Date 28/03/19 01/04/20 24/05/21 21/04/22 31/03/23 22/03/24
1IDR in Million2IDR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 16,99,657 18,13,020 18,29,700 19,00,894 19,17,041 18,90,888
EBITDA 1 3,08,345 3,58,027 2,64,612 2,51,421 2,48,677 2,47,360
EBIT 1 2,58,597 3,04,096 2,08,503 1,95,702 1,89,966 1,86,186
Operating Margin 15.21% 16.77% 11.4% 10.3% 9.91% 9.85%
Earnings before Tax (EBT) 1 2,72,844 3,01,250 2,14,069 2,11,794 2,01,073 1,91,638
Net income 1 2,00,652 2,21,783 1,62,073 1,46,726 1,49,375 1,46,336
Net margin 11.81% 12.23% 8.86% 7.72% 7.79% 7.74%
EPS 2 179.8 198.2 144.7 131.0 133.4 130.7
Free Cash Flow 1 -31,684 1,64,033 48,670 3,05,182 -1,20,339 -7,999
FCF margin -1.86% 9.05% 2.66% 16.05% -6.28% -0.42%
FCF Conversion (EBITDA) - 45.82% 18.39% 121.38% - -
FCF Conversion (Net income) - 73.96% 30.03% 208% - -
Dividend per Share 2 107.0 107.0 110.0 114.0 119.0 108.0
Announcement Date 28/03/19 01/04/20 24/05/21 21/04/22 31/03/23 22/03/24
1IDR in Million2IDR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 3,06,117 3,39,047 2,64,324 5,60,315 3,55,133 2,38,569
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -31,684 1,64,033 48,670 3,05,182 -1,20,339 -7,999
ROE (net income / shareholders' equity) 17.3% 17.7% 12.3% 10.8% 10.7% 10.4%
ROA (Net income/ Total Assets) 9.73% 10.8% 6.83% 6.01% 5.8% 5.74%
Assets 1 20,63,174 20,49,563 23,73,409 24,42,740 25,74,189 25,47,373
Book Value Per Share 2 1,076 1,167 1,184 1,233 1,253 1,254
Cash Flow per Share 2 274.0 303.0 237.0 521.0 319.0 214.0
Capex 1 45,488 58,955 62,807 84,944 58,185 97,916
Capex / Sales 2.68% 3.25% 3.43% 4.47% 3.04% 5.18%
Announcement Date 28/03/19 01/04/20 24/05/21 21/04/22 31/03/23 22/03/24
1IDR in Million2IDR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
PT DARYA-VARIA LABORATORIA TBK Stock PT Darya-Varia Laboratoria Tbk
-8.71% 104M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 815B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.05% 641B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
NOVARTIS AG Stock Novartis AG
+13.31% 218B
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
PFIZER, INC. Stock Pfizer, Inc.
-2.81% 159B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. DVLA Stock
  4. Financials PT Darya-Varia Laboratoria Tbk